Verastem Inc (VSTM)
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business